Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Genomic and immune profiling of prognostic groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P e.g. CXCR4, KMT2D, ARID1A and EP300 mutations, upregulated genes involved in NF-κB and BCR signaling activation.”
Title: Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P
Authors: David F. Moreno, Ferran Nadeu, Fara Brasó-Maristany, Sergi Vaqué, Sara Paz, Joan Mañé, Oriol Cardús, Elena Medina, Ester Lozano, Luis Gerardo Rodríguez-Lobato, Anna de Daniel, Natalia Tovar, María T. Cibeira, Joan Bladé, Laura Rosiñol, Aleix Prat, Dolors Colomer, Carlos Fernández de Larrea.
You can read the Full Article in Frontiers in Immunology.
You can find more posts featuring Robert Orlowski in OncoDaily.
